Dr. Tim Greten receives 2024 Innovation Grant from the Cholangiocarcinoma Foundation! – NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn:
“STAFF SPOTLIGHT: Congratulations to Dr. Tim Greten, the deputy chief of our Thoracic and GI Malignancies Branch, for being the recipient of a 2024 Innovation Grant from the Cholangiocarcinoma Foundation!
Cholangiocarcinoma is an aggressive cancer of the bile duct. Dr. Greten conducts investigator-initiated first-in-human trials, phase I and II trials and has been one of the first investigators to test immune checkpoint inhibitors in patients with Hepatocellular carcinoma and Cholangiocarcinoma either alone or in combination with locoregional therapies.
He and his team cover the entire research spectrum from basic tumor immunology and the use of complex murine cancer models to the development and evaluation of new immunotherapies (including CAR T cells) for patients with gastrointestinal cancers.”